The University of Toronto, Lab of Dr. David Lovejoy

Technology born in David Lovejoy’s lab


Protagenic Therapeutics owns an exclusive, worldwide license to commercialize technology discovered at the University of Toronto. This includes PTI’s lead compound, PT00114, along with subsequent versions of the TCAP neuropeptide family of compounds. Drs. Lovejoy and Barsyte are active contributors to the advancement of PTI’s R&D programs, and work side-by-side with our operating team as we progress the technology they discovered years ago.